United Therapeutics Corpo... (UTHR)

NASDAQ: UTHR · Real-Time Price · USD

299.33

-3.76 (-1.24%)

At close: May 01, 2025, 11:52 AM

-1.24% (1D)

Bid	299.21
Market Cap	13.44B
Revenue (ttm)	2.88B
Net Income (ttm)	1.2B
EPS (ttm)	25.1
PE Ratio (ttm)	11.93
Forward PE	10.44
Analyst	Buy

Ask	300.35
Volume	118,932
Avg. Volume (20D)	510,649
Open	304.79
Previous Close	303.09
Day's Range	293.95 - 304.60
52-Week Range	253.93 - 417.82
Beta	0.63

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 17, 1999

Employees 1,305

Stock Exchange NASDAQ

Ticker Symbol UTHR

Website https://www.unither.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is $355, which is an increase of 18.60% from the latest price.

Stock Forecasts

Earnings Surprise

New

United Therapeutics has released their quartely earnings on Apr 30, 2025:

Revenue of $794.4M exceeds estimates by $64.58M, with 17.22% YoY growth.

EPS of 6.63 exceeds estimates by 0.10, with 7.46% YoY growth.

Why Price Moved

2 months ago

-10.8%

United Therapeutics shares are trading lower after... Unlock content with Pro Subscription

8 months ago

+3.04%

United Therapeutics shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $400 to $572.

News

Just now · zacks.com

UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales

United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.

1 day ago · seekingalpha.com

United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript

United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairpers...

17 hours ago · zacks.com

United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metri...

19 hours ago · zacks.com

United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $6.63 per share, beating the Zacks Consensus Estimate of $6.29 per share. This compares to earnings of $6.17 per share a year ago.

21 hours ago · businesswire.com

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...

1 week ago · zacks.com

United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

2 weeks ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

3 weeks ago · zacks.com

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 weeks ago · businesswire.com

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations acr...

Load More News